Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/14/2796207/0/en/Rani-Therapeutics-Announces-Preclinical-Pharmacodynamic-Data-on-Transenteric-Delivery-of-GLP-1-Incretin-Triagonist.html

– Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –

– Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments –

Read more at globenewswire.com

Related news for (RANI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.